Enanta Pharmaceuticals
ENTA
156 hedge funds and large institutions have $928M invested in Enanta Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 63 increasing their positions, 48 reducing their positions, and 33 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 48
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.84% less ownership
Funds ownership: 93.32% → 90.49% (-2.8%)
9% less funds holding
Funds holding: 171 → 156 (-15)
18% less capital invested
Capital invested by funds: $1.14B → $928M (-$209M)
26% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $3.15M
42% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAM
Krensavage Asset Management
New York
|
+$11.2M |
| 2 |
AC
Armistice Capital
New York
|
+$9.28M |
| 3 |
Renaissance Technologies
New York
|
+$7.94M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.15M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$5.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$39.7M |
| 2 |
Morgan Stanley
New York
|
-$8.95M |
| 3 |
MCM
Matarin Capital Management
New York
|
-$8.41M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$8.05M |
| 5 |
First Manhattan
New York
|
-$7.15M |
ENTA Hedge Fund Activity: Q1 2020 in Review
156 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2020, worth a combined $928M — down 18% from $1.14B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of ENTA and 19 opened new positions — a net loss of 14 holders — while 48 trimmed existing stakes and 63 added.
The largest buyer was Krensavage Asset Management, adding an estimated $11.2M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $39.7M sold.
- 156 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2020, down from 171 in Q4 2019.
- Funds reported $928M of Enanta Pharmaceuticals stock for Q1 2020, down 18% quarter-over-quarter.
- 19 funds opened new Enanta Pharmaceuticals positions in Q1 2020 and 33 closed out, a net change of -14 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2020 was Krensavage Asset Management, an estimated $11.2M added.
- The largest Enanta Pharmaceuticals seller in Q1 2020 was Janus Henderson Group, an estimated $39.7M sold.
Based on aggregated 13F filings for Q1 2020.